Skip to content
2000
Volume 18, Issue 11
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Background: Recent reports indicate that the tumor microenvironment plays a pivotal role in cancer development and progression, leading to a paradigm shift in the way cancer is studied and targeted. In contrast to traditional approaches, where only tumor cells are targeted for the treatment, an emerging approach is to develop therapeutics which target the tumor microenvironment while complementing or enhancing current treatments. Legumain (LGMN) is a newly identified target which is highly expressed in the tumor microenvironment and in tumor cells, and holds potential both as a biomarker and as a therapeutic target. Conclusion: This review will be the first to summarize the expression of LGMN in common cancers, as well as its roles in tumorigenesis and metastasis. This review also discusses the current developments and future prospects of targeting LGMN through the development of DNA vaccines, azopeptides, small molecule inhibitors and LGMN activated prodrugs, highlighting the potential of LGMN as a target for cancer therapeutics.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450117666161216125344
2017-09-01
2025-05-23
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450117666161216125344
Loading

  • Article Type:
    Research Article
Keyword(s): azo-peptide; cancer; Legumain; prodrug; small molecules; tumor microenvironment; vaccine
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test